666-P: CGM Access Is the Main Barrier to TIR Use among Providers

Abstract

Background and Aims: Previous studies have shown a correlation between Time in Range (TIR) and risk for microvascular complications, but the metric is not used widely in diabetes care. This study aimed to assess the barriers to TIR use among healthcare providers. Methods: In an online survey in September 2021, 303 HCPs, each working with a minimum of 30 patients with diabetes each month, were asked a series of questions related to challenges, evaluation, and goal-setting when discussing diabetes management with their patients. Respondents were classified as either Endocrinologists (Endo) , Diabetes Educators (DE) , or primary care providers (PCP) . Statistical significance was tested at the 95% confidence level (p<0.05) . Results: 80% of HCPs who use TIR (n=234) identify access to CGM as a main drawback of TIR and 72% (n=289) identified cost as a downside of CGM use. When TIR non-users (n=64) were asked what would convince them to use TIR with patients, 41% cited increased access to CGM and 30% cited training and resources about how to use TIR data. 83% of non-users (n=64) believe TIR would be useful in their diabetes care. When asked what would improve their diabetes care, 39% of HCPs said having more patients on CGM and 28% said the ability to use TIR data with more patients (n=246) . Conclusions: This data highlights the barriers to TIR adoption and use among HCPs. Increased access to CGM and education on TIR use in clinical practice can help advance TIR in diabetes care. Disclosure J.Kenney: None. J.Tait: Employee; dQ&A. A.Briskin: None. E.Shoger: Other Relationship; Diabetes industry. R.Wood: Other Relationship; Multiple companies and patient organizations (>10) . A.L.Peters: Advisory Panel; Abbott Diabetes, AstraZeneca, Eli Lilly and Company, Novo Nordisk, Shouti, Vertex Pharmaceuticals Incorporated, Zealand Pharma A/S, Other Relationship; Omada Health, Inc., Research Support; Abbott Diabetes, Dexcom, Inc., Insulet Corporation, Leona M. and Harry B. Helmsley Charitable Trust, Stock/Shareholder; Teladoc Health.